Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association

Diane Treat-Jacobson, Mary M. McDermott, Ulf G Bronas, Umberto Campia, Tracie C. Collins, Michael H. Criqui, Andrew W. Gardner, William R. Hiatt, Judith G. Regensteiner, Kathleen Rich

Research output: Contribution to journalArticlepeer-review

25 Scopus citations
Original languageEnglish (US)
Pages (from-to)E10-E33
JournalCirculation
Volume139
Issue number4
DOIs
StatePublished - Jan 22 2019

Bibliographical note

Funding Information:
AstraZeneca (clinical trial research grant to study ticagrelor in PAD)*; Bayer (clinical trial research grant to study rivaroxaban in PAD)†; Pluristem (clinical research grant of a stem cell product in PAD)*; NIH (multicenter clinical trial in venous thrombosis)†

Funding Information:
ACI Medical (supplied pneumatic compression devices for a pilot study)*; Chromadex (supplied drug for study)†; Hershey’s Company (supplied drug for study)†; NHLBI (funding from 4 ongoing research grants)†; NIA†; PCORI†; Regeneron†; Reserveage (supplied drug for study on resveratrol)*; Viromed (supplied drug for study)†

Keywords

  • AHA Scientific Statements
  • exercise
  • exercise therapy
  • intermittent claudication
  • peripheral artery disease

Cite this